Financial Performance - The estimated net profit attributable to shareholders for 2024 is projected to be between 117 million and 125 million CNY, representing a decrease of 51.95% to 55.02% compared to the previous year's profit of 260.13 million CNY [3]. - The estimated net profit after deducting non-recurring gains and losses is projected to be between 32 million and 40 million CNY, reflecting a decline of 76.21% to 80.97% from the previous year's profit of 168.16 million CNY [3]. - Non-recurring gains and losses are expected to impact the net profit attributable to shareholders by approximately 85 million CNY, down from 91.98 million CNY in the previous year [6]. Business Focus and Revenue - The company continues to focus on its core business of biological reagent products and services, with conventional business revenue maintaining steady growth [5]. - Non-conventional business revenue has significantly declined due to external environment changes and market demand fluctuations [5]. - The company has made substantial investments in business expansions in Suzhou, Taizhou, Canada (SCB), and the U.S. (C4B), which have resulted in delayed returns [5]. Financial Reporting - The financial data presented is preliminary and has not been audited, with detailed financial information to be disclosed in the 2024 annual report [7].
义翘神州(301047) - 2024 Q4 - 年度业绩预告